Carmeda Coating On GORE-TEX PROPATEN Vascular Graft Recently Launched in Europe.Business Editors & Health/Medical Writers BIOWIRE2K SAN ANTONIO--(BW HealthWire)--May 30, 2002 The Carmeda BioActive Surface (CBAS CBAS Command Budget Automated System CBAS Computrols Building Automation System (building automation software) CBAS Computerized Building Automation System CBAS Corporate Business Applications Support (tm)) is now being sold in Europe on W.L. Gore and Associates' GORE-TEX(R) PROPATEN(tm) vascular graft. Gore joins several other prominent medical device companies which utilize the Carmeda(R) surface technology, companies including Medtronic, Cordis, a Johnson and Johnson company, and Diametrics. Gore's product literature highlights two important aspects of the Carmeda surface. First, Gore points to "sustained heparin activity on GORE-TEX PROPATEN vascular grafts." Animal studies revealed significant heparin activity on coated vascular grafts explanted from arteries twelve weeks post-op. And a canine carotid artery carotid artery n. 1. An artery that originates on the right from the brachiocephalic artery and on the left from the aortic arch, runs upward into the neck and divides opposite the upper border of the thyroid cartilage, with the external and model utilizing 3mm diameter grafts demonstrated a dramatic improvement in coated versus uncoated graft patency pa·ten·cy n. The state or quality of being open, expanded, or unblocked. patency the condition of being open. as far out as 180 days. "The European market launch of the GORE-TEX PROPATEN vascular graft reinforces Carmeda's position as the leader in hemocompatible coating technology for long-term blood contacting device applications," states Krister Ljungqvist, Managing Director of Carmeda. He adds "We are pleased to be partnering with Gore, the long-time leader in the vascular graft market." The Carmeda surface is a proprietary heparin coating which retains thromboresistant properties for periods lasting several months. This long-term bioactivity bi·o·ac·tiv·i·ty n. The effect of a given agent, such as a vaccine, upon a living organism or on living tissue. , coupled with the fact that the stable heparin coating does not leave the device surface, differentiates the Carmeda surface from other coatings designed to improve the hemocompatibility of blood-contacting devices. The Carmeda surface is the most prevalent and clinically proven thromboresistant coating applied to critical medical devices by U.S. and European device manufacturers. Since 1985 Carmeda has commercialized the "end-point attachment" of immobilized heparin molecules to medical device surfaces. Carmeda AB (Stockholm) is majority owned by Norsk Hydro ASA Asa (ā`sə), in the Bible, king of Judah, son and successor of Abijah. He was a good king, zealous in his extirpation of idols. When Baasha of Israel took Ramah (a few miles N of Jerusalem), Asa bought the help of Benhadad of Damascus and (ADR ADR - Astra Digital Radio ) (NYSE NYSE See: New York Stock Exchange :HYDRO). For additional information please visit www.carmeda.com. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion